AlphaCore Pharma

Industry

  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
See more in Biomedtracker

Latest on AlphaCore Pharma

Pink Sheet

Deal Watch: Auxilium Accepts Endo Buyout Rather Than Completing Purchase Of QLT Shell

 
• By Lisa LaMotta, John Davis, and Sten Stovall

“The Pink Sheet” regularly presents commentary and perspective on key business deals. Here is a summary of the most noteworthy transactions that occurred between Oct. 4 and Oct. 10. Endo/Auxilium It

In Vivo

Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues

A summertime overhaul of business development structure and personnel at AstraZeneca PLC decentralizes much of the group’s activities and aligns them with specific therapeutic area strategies. Mea

Pink Sheet

AZ Builds Cardiac Regeneration, Diabetes R&D At Swedish Research Hub

 
• By John Davis

AstraZeneca PLC 's early-stage cardiovascular and metabolic research is focusing on expected patient needs in the period 2020 to 2025, in three relatively narrow therapeutic areas: cardiac regenerati

Scrip

AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself

 
• By Paul Bonanos

AstraZeneca PLC became the second pharma to bet that FibroGen Inc. ’s lead anemia program will produce a blockbuster, when it took China rights to the drug FG-4592 for $350 million up front. The